ABBOTT LABORATORI…
USUSDABBOTT LABORATORIES (XETRA:ABL) — Biotechnology: Pharmaceutical Preparations. Antal børser, hvor selskabets aktier handles: 4. På denne side — kurs og diagram, udbytte, største aktionærer og historik over antal aktier.
Om Virksomheden
- Websted
- abbott.com
- Sektor
- Health Care · Biotechnology: Pharmaceutical Preparations
- Hovedkontor
- North Chicago, United States
- Administrerende Direktør
- Robert Ford
- Ansatte
- 73 000
- Grundlagt
- 1888
- Børsnoteret Siden
- 20.12.2007 (XETRA:ABL)
- Udestående Aktier
- 1.73 mia. pr. 2026-06-30
- Free Float
- 1.72 mia.
- Markedsværdi
- 169.83 mia. USD
- Insidere
- 0.49%
- Institutionelle Investorer
- 81.79%
- Branche (SIC)
- Pharmaceutical Preparations
- Juridisk Form
- AZUK
- ISIN
- US0028241000
- LEI
- HQD377W2YR662HK5JX27
- P/E
- 33.4
- Udbetalingsgrad
- 66.7%
- FCF
- 7.38 mia. USD
- Udbetaling / FCF
- 57%
- Gæld
- 34.0 mia. USD3.7 år FCF
- Udbyttestreak
- 43 år
- Indtjening, FCF og udbetalt udbytte — for de 12 måneder frem til 31.03.2026 (selskabets seneste rapport).
- NAV
Beskrivelse
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
Udbytte
ABBOTT LABORATORIES (ABL) udbetaler udbytte kvartalsvis. Pr. År (12 måneder op til og med den senest annoncerede betaling): 1.6798 EUR pr. Aktie (betalinger: 3). Det svarer til cirka 1.89% af den nuværende aktiekurs. Baseret på betalingshistorikken forventes næste ex-udbyttedato omkring 13.01.2027. Uafbrudt udbyttehistorik: 43 år.
| Ex-Dato | Udbetaling | Beløb | % | Type | Ticker |
|---|---|---|---|---|---|
| 2026-07-15 | — | 0.5599 EUR | 0.7/2.8 % | kvartalsvis | XETRA:ABL |
| 2026-04-15 | — | 0.5599 EUR | 0.6/2.5 % | kvartalsvis | XETRA:ABL |
| 2026-01-15 | — | 0.5599 EUR | 0.5/2.0 % | kvartalsvis | XETRA:ABL |
| 2025-10-15 | — | 0.5244 EUR | 0.5/1.8 % | kvartalsvis | XETRA:ABL |
| 2025-07-15 | — | 0.5244 EUR | 0.5/1.8 % | kvartalsvis | XETRA:ABL |
| 2025-04-15 | — | 0.5244 EUR | 0.5/1.8 % | kvartalsvis | XETRA:ABL |
| 2025-01-15 | — | 0.5244 EUR | 0.5/1.8 % | kvartalsvis | XETRA:ABL |
| 2024-10-15 | — | 0.4888 EUR | 0.5/1.8 % | kvartalsvis | XETRA:ABL |
| 2024-07-15 | — | 0.4888 EUR | 0.5/2.0 % | kvartalsvis | XETRA:ABL |
| 2024-04-12 | — | 0.4888 EUR | 0.5/1.8 % | kvartalsvis | XETRA:ABL |
| 2024-01-11 | — | 0.4888 EUR | 0.5/1.8 % | kvartalsvis | XETRA:ABL |
| 2023-10-12 | — | 0.4533 EUR | 0.5/2.0 % | kvartalsvis | XETRA:ABL |
| 2023-07-13 | — | 0.4533 EUR | 0.5/1.8 % | kvartalsvis | XETRA:ABL |
| 2023-04-13 | — | 0.4533 EUR | 0.5/1.9 % | kvartalsvis | XETRA:ABL |
| 2023-01-12 | — | 0.4533 EUR | 0.4/1.6 % | kvartalsvis | XETRA:ABL |
| 2022-10-13 | — | 0.4177 EUR | 0.4/1.6 % | kvartalsvis | XETRA:ABL |
| 2022-07-14 | — | 0.4177 EUR | 0.4/1.2 % | kvartalsvis | XETRA:ABL |
| 2022-04-13 | — | 0.4177 EUR | 0.4/0.8 % | kvartalsvis | XETRA:ABL |
| 2022-01-13 | — | 0.4177 EUR | 0.4/0.4 % | kvartalsvis | XETRA:ABL |
Nyheder Denne Uge
Pressemeddelelser fra virksomhedens investorhjemmeside, opdateret dagligt. Links fører til virksomhedens hjemmeside. Overskrifterne er på originalsproget, som på virksomhedens hjemmeside.
| 13.10.2026 | Newsroom | Top Stories |
Største Ejere
| Ejer | Andel | Aktier | Rapportdato |
|---|---|---|---|
| BlackRock | 8.82% | 152.56 mio. | 2026-06-30 |
| Vanguard Capital Managem… | 6.57% | 113.75 mio. | 2026-06-30 |
| State Street Corporation | 4.68% | 80.93 mio. | 2026-06-30 |
| Charles Schwab Investmen… | 3.45% | 59.67 mio. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3.2% | 55.3 mio. | 2026-06-30 |
| Vanguard Portfolio Manag… | 2.83% | 49.02 mio. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.61% | 45.14 mio. | 2026-06-30 |
| Geode Capital Management… | 2.27% | 39.22 mio. | 2026-06-30 |
| Capital Research Global… | 2.13% | 36.91 mio. | 2026-06-30 |
| Capital International In… | 2% | 34.65 mio. | 2026-06-30 |
| SCHWAB STRATEGIC TRUST-S… | 1.9% | 32.82 mio. | 2026-05-31 |
| Morgan Stanley | 1.54% | 26.61 mio. | 2026-06-30 |
| NORGES BANK | 1.35% | 23.35 mio. | 2026-06-30 |
| iShares Trust-iShares Co… | 1.34% | 23.2 mio. | 2026-08-31 |
| Fidelity Concord Street… | 1.3% | 22.52 mio. | 2026-07-31 |
| SPDR S&P 500 ETF TRUST-S… | 1.23% | 21.31 mio. | 2026-08-31 |
| WASHINGTON MUTUAL INVEST… | 1.01% | 17.53 mio. | 2026-07-31 |
| VANGUARD INDEX FUNDS-Van… | 0.96% | 16.58 mio. | 2026-06-30 |
| SELECT SECTOR SPDR TRT-S… | 0.72% | 12.52 mio. | 2026-08-31 |
| Investment Co of America | 0.6% | 10.33 mio. | 2026-06-30 |
| STARKS DANIEL J (Directo… | ≈0.39% | 6.75 mio. | 2026-04-27 |
| FORD ROBERT B. (Chief Ex… | ≈0.03% | 522 664 | 2026-08-25 |
| ALLEN HUBERT L. (Officer… | ≈0.01% | 200 281 | 2025-02-25 |
| SALVADORI DANIEL GESUA S… | ≈0.01% | 146 377 | 2026-03-02 |
| CONROY KEVIN T (Director… | ≈0.01% | 133 737 | 2026-04-24 |
| MORELAND MARY K (Officer… | ≈0.01% | 116 136 | 2026-03-02 |
| EARNHARDT LISA D (Office… | ≈0.01% | 98 984 | 2026-02-24 |
| SCOGGINS CHRISTOPHER J (… | ≈0% | 82 123 | 2026-02-24 |
| WAINER ANDREA F (Officer… | ≈0% | 74 381 | 2025-03-03 |
| The Vanguard Group | — | — | — |
| BOUDREAU PHILIP P (Chief… | — | — | 2026-04-23 |
